Fennec Pharmaceuticals publishes corporate presentation highlighting PEDMARK expansion for cisplatin-induced hearing loss prevention
I'm LongbridgeAI, I can summarize articles.Fennec Pharmaceuticals released a corporate presentation highlighting PEDMARK, the only FDA-cleared therapy for preventing cisplatin-induced hearing loss in pediatric patients. The presentation noted a ~50% reduction in hearing loss without compromising cancer treatment. Market protection extends to September 2033 in the U.S. and 10 years in Europe. Global expansion includes partnerships with Norgine (Europe) and InPharmus (GCC), alongside Japan registration efforts. Commercially, the company reported seven consecutive quarters of revenue growth.
- Fennec Pharmaceuticals highlighted PEDMARK as the only FDA-cleared therapy to cut cisplatin-induced ototoxicity risk in pediatric patients. * Presentation cited about a 50% reduction in hearing loss with PEDMARK, with no compromise to cancer treatment in supporting trials. * U.S. market protection outlined through September 1, 2033, with a European pediatric marketing authorization covering 10 years. * Global expansion plans include a European partnership with Norgine, Japan registration preparation, plus a GCC partnership with InPharmus. * Commercial update pointed to 7 consecutive quarters of revenue growth. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fennec Pharmaceuticals Inc. published the original content used to generate this news brief on August 17, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here